DexCom, Inc. (NASDAQ:DXCM - Get Free Report) CEO Kevin R. Sayer sold 49,633 shares of the firm's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the sale, the chief executive officer now directly owns 283,893 shares in the company, valued at approximately $39,262,401.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
DexCom Price Performance
NASDAQ DXCM opened at $140.32 on Thursday. The stock has a market cap of $54.10 billion, a price-to-earnings ratio of 107.12, a PEG ratio of 2.40 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company's 50 day moving average is $127.91 and its two-hundred day moving average is $114.71.
DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company's revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.34 earnings per share. As a group, research analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.
Institutional Investors Weigh In On DexCom
4 Cryptos BETTER than Bitcoin
From True Market Insiders | Ad
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Click For My #1 FREE Crypto for 2024
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of DexCom by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 44,467,463 shares of the medical device company's stock valued at $5,517,967,000 after buying an additional 278,458 shares during the last quarter. Capital Research Global Investors raised its position in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company's stock valued at $1,898,085,000 after buying an additional 2,695,296 shares during the last quarter. Sands Capital Management LLC raised its position in shares of DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company's stock valued at $1,868,647,000 after buying an additional 1,398,136 shares during the last quarter. Capital World Investors grew its holdings in shares of DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company's stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of DexCom by 2.1% in the first quarter. Geode Capital Management LLC now owns 8,282,663 shares of the medical device company's stock valued at $960,174,000 after purchasing an additional 170,796 shares in the last quarter. Institutional investors own 97.75% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on DXCM shares. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target on the stock. Citigroup raised their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Piper Sandler raised their price objective on shares of DexCom from $135.00 to $150.00 and gave the stock an "overweight" rating in a report on Tuesday, December 19th. UBS Group raised their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wells Fargo & Company raised their price objective on shares of DexCom from $110.00 to $136.00 and gave the stock an "overweight" rating in a report on Wednesday, December 13th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, DexCom currently has an average rating of "Moderate Buy" and an average target price of $141.40.
View Our Latest Report on DexCom
About DexCom
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
